Feedback / Questions
Cosentyx (secukinumab) - Novartis
Cosentyx: Regulatory decision in China for ankylosing spondylitis in H1 2020
(Novartis)
-
Jan 29, 2020 -
Q4 and FY 2019 Results: Regulatory decision in EU for pediatric psoriasis in H2 2020
European regulatory • Non-US regulatory
https://www.novartis.com/sites/www.novartis.com/files/q4-2019-investor-presentation.pdf
Jan 29, 2020
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious